# Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Study · id `cardio:ct-nct06906081` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06906081](<https://clinicaltrials.gov/study/NCT06906081>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06906081

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06906081. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-02 (actual); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06906081, source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)
- Started: 2025-05-02 (actual) (ClinicalTrials.gov record NCT06906081, source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT06906081, source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)
- Completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT06906081, source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06906081, source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06906081-2025-05-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
- Acronym: FibroCAN
- Condition: Cardiovascular Autonomic Neuropathy
- Condition: Type 2 Diabetes
- Condition: Diabetic Neuropathies
- Intervention (Drug): Kerendia (Finerenone, BAY94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: Peter Rossing
- Lead sponsor class: OTHER
- Collaborator: Steno Diabetes Center Nordjylland
- Collaborator class: OTHER
- Collaborator: Aarhus University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (Kerendia) (`cardio:kerendia`)
- Registry lists this organization as the lead sponsor: Peter Rossing (`cardio:org-peter-rossing`)
- Registry lists this organization as a collaborator: Steno Diabetes Center Nordjylland (`cardio:org-steno-diabetes-center-nordjylland`)
- Registry lists this organization as a collaborator: Aarhus University Hospital (`cardio:org-aarhus-university-hospital`)

## Provenance

Content hash: 7f7eca9eef0c07ecb63858ce810cac6f615940ccc33409b96a457788cc0d9328
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
